Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Average Rating of "Moderate Buy" by Brokerages

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $27.40.

A number of equities analysts have recently weighed in on OTLK shares. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Outlook Therapeutics in a research note on Friday, January 17th. Guggenheim reaffirmed a "buy" rating and set a $12.00 price target on shares of Outlook Therapeutics in a research note on Friday, January 17th. BTIG Research lowered their price target on shares of Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating on the stock in a research note on Friday, November 29th. Finally, Chardan Capital reaffirmed a "neutral" rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd.

Institutional Investors Weigh In On Outlook Therapeutics

A number of large investors have recently added to or reduced their stakes in OTLK. Rhumbline Advisers grew its stake in Outlook Therapeutics by 1,329.6% in the 4th quarter. Rhumbline Advisers now owns 188,050 shares of the company's stock valued at $355,000 after acquiring an additional 174,896 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Outlook Therapeutics by 49.2% during the 3rd quarter. Geode Capital Management LLC now owns 341,959 shares of the company's stock worth $1,826,000 after purchasing an additional 112,812 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Outlook Therapeutics during the 3rd quarter worth about $199,000. Squarepoint Ops LLC acquired a new stake in shares of Outlook Therapeutics during the 2nd quarter worth about $232,000. Finally, Commonwealth Equity Services LLC acquired a new stake in shares of Outlook Therapeutics during the 4th quarter worth about $48,000. 11.20% of the stock is owned by institutional investors and hedge funds.

Outlook Therapeutics Stock Performance

Outlook Therapeutics stock traded down $0.09 during trading hours on Friday, reaching $1.63. 342,089 shares of the stock were exchanged, compared to its average volume of 918,043. The stock has a market cap of $51.97 million, a P/E ratio of -0.18 and a beta of 0.58. Outlook Therapeutics has a 52-week low of $0.87 and a 52-week high of $12.85. The firm's 50 day moving average is $1.87 and its 200 day moving average is $4.70.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last announced its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.06. Equities research analysts expect that Outlook Therapeutics will post -2.25 EPS for the current fiscal year.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.